Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » What are the options available for medication prior to IUD placement?

    What are the options available for medication prior to IUD placement?

    September 1, 2015
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    The IUD and PID: What are the risks?

    Misoprostol Prior to IUD Insertion in Nulliparous Women: Where’s the Benefit?

    What are the options when it comes to OCs?

    Related Products

    Concomitant Hysteroscopic Sterilization and Endometrial Ablation: What Are the Risks?

    Immediate Postpartum IUD Insertion: Ready for Prime Time?

    Integrative Treatment for Restless Legs Syndrome: What Does the Evidence Say?

    Executive Summary

    New research looks at the use of ketorolac, an injectable drug often used in the postoperative setting, as a possible option for easing pain prior to intrauterine device (IUD) insertion.

    • While the American College of Obstetricians and Gynecologists recommends taking over-the-counter pain medication prior to IUD insertion, no specific drug is recommended.
    • While ketorolac doesn’t reduce pain with IUD placement, it does reduce pain at five and 15 minutes after placement, researchers note. However, use of the drug calls for a potentially painful intramuscular injection and an in-clinic 30-minute wait time.

    While the American College of Obstetricians and Gynecologists recommends taking over-the-counter pain medication prior to intrauterine device (IUD) insertion, no specific drug is recommended.1 Research has just been published that looks at the use of ketorolac, an injectable drug often used in the postoperative setting.2

    To evaluate the use of intramuscular injection of ketorolac compared with placebo saline injection for pain control with IUD placement, researchers conducted a randomized, double-blind, placebo-controlled trial between July 2012 and March 2014. Patients received 30 mg ketorolac or placebo saline intramuscular injection 30 minutes before IUD placement. The primary outcome was pain with IUD placement on a 10-cm visual analog scale. Sample size was calculated to provide 80% power to show a 2.0-cm difference (p=0.05) in the primary outcome. Secondary outcomes included pain with study drug injection, speculum insertion, tenaculum placement, uterine sounding, and at five and 15 minutes after IUD placement. Sixty-seven women participated in the study; 33 were placed in the ketorolac arm, and 34 were placed in the placebo arm. There were no differences in baseline demographics including age, body mass index, and race.

    In the data analysis, there were no differences in median pain scores for IUD placement in the placebo compared with ketorolac groups (5.2 compared with 3.6 cm, p=.99). While there was a decrease in median pain scores at five minutes (2.2 compared with 0.3 cm, p?.001) and 15 minutes (1.6 compared with 0.1 cm, p?.001) after IUD placement, no difference was noted for all other time points. Nulliparous participants (n=16, eight per arm) had a decrease in pain scores with IUD placement (8.1 compared with 5.4 cm, p=.02). In this study, 22% of participants in the placebo group and 18% in the ketorolac group reported injection pain was as painful as IUD placement.1 While ketorolac did not reduce pain with IUD placement, it did reduce pain at five and 15 minutes after placement, the researchers conclude.

    “The demonstrated efficacy of ketorolac in this study is encouraging,” the scientists note. “However, it is limited by the need for a potentially painful intramuscular injection and an in-clinic 30-minute wait time.”

    Is injection worth it?

    As the study authors point out, the maximum analgesia provided by ketorolac occurs 1-2 hours post-injection, notes Andrew Kaunitz, MD, University of Florida Research Foundation professor and associate chairman of the Department of Obstetrics and Gynecology at the University of Florida College of Medicine – Jacksonville. This observation might explain why pain reduction was noted only after the procedure, he points out. While ketorolac is not expensive, logistical considerations might make routine use of pre-IUD placement injectable analgesia unrealistic in many ambulatory settings, says Kaunitz.

    Prior studies suggest that pre-placement oral nonsteroidal anti-inflammatory drugs (NSAIDs) aren’t effective in reducing placement pain involving analgesic administration in the clinic less than one hour pre-IUD placement.3 Kaunitz agrees with the study authors that future trials of oral NSAID administration prior to arrival at the clinic are warranted.

    What are the options?

    A comparative study design against oral NSAIDs would be appropriate before ketorolac use is endorsed, says Anita Nelson, MD, professor in the Obstetrics and Gynecology Department at the David Geffen School of Medicine at the University of California in Los Angeles.

    Studies that have looked at IUD insertions indicate that there is no treatment effective for general use for pain associated with device placement,4-7 notes Nelson. Nelson presented information on contraception at the April 2014 Montana Family Planning Training in Helena.

    Results from a 2011 study conducted to examine the effects of prophylactic misoprostol prior to intrauterine device placement in nulliparous women suggest the drug did not reduce patient perceived pain, but it did appear to increase preinsertion side effects,8 Nelson comments.

    A 2013 literature review indicates that NSAIDs do reduce later cramping and bleeding associated with new Copper T380A IUD users,9 says Nelson.

    REFERENCES

    1. American College of Obstetricians and Gynecologists. Long-acting reversible contraception (LARC): IUD and implant. Accessed at http://bit.ly/1BtCEp8.
    2. Ngo LL, War KK, Mody SK. Ketorolac for pain control with intrauterine device placement: A randomized controlled trial. Obstet Gynecol 2015; 126(1):29-36.
    3. Allen RH, Bartz D, Grimes DA, et al. Interventions for pain with intrauterine device insertion. Cochrane Database Syst Rev 2009; doi: 10.1002/14651858.CD007373.pub2.
    4. Hubacher D, Reyes V, Lillo S, et al. Pain from copper intrauterine device insertion: Randomized trial of prophylactic ibuprofen. Am J Obstet Gynecol 2006; 195(5):1272-1277.
    5. Dijkhuizen K, Dekkers OM, Holleboom CA, et al. Vaginal misoprostol prior to insertion of an intrauterine device: An RCT. Hum Reprod 2011; 26(2):323-329.
    6. Chor J, Bregand-White J, Golobof A, et al. Ibuprofen prophylaxis for levonorgestrel-releasing intrauterine system insertion: A randomized controlled trial. Contraception 2012; 85(6):558-562.
    7. Allen RH, Raker C, Goyal V. Higher dose cervical 2% lidocaine gel for IUD insertion: A randomized controlled trial. Contraception 2013; 88(6):730-736.
    8. Edelman AB, Schaefer E, Olson A, et al. Effects of prophylactic misoprostol administration prior to intrauterine device insertion in nulliparous women. Contraception 2011; 84(3):234-239.
    9. Godfrey EM, Folger SG, Jeng G, et al. Treatment of bleeding irregularities in women with copper-containing IUDs: A systematic review. Contraception 2013; 87(5):549-566.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Contraceptive Technology Update

    View PDF
    Contraceptive Technology Update 2015-09-01
    September 1, 2015

    Table Of Contents

    Counseling on LARC methods cuts unintended pregnancy rates

    Single-size Caya diaphragm is available by prescription in U.S.

    What are the options available for medication prior to IUD placement?

    Long-acting reversible contraceptives used by few women after delivery

    Study: Obese teens less likely to use contraception

    Gay, lesbian, and bisexual youth grouped, show increased risk for unintended pregnancy

    Liletta IUD available in the United States

    Time to update your clinical practice: 2015 STD Treatment Guidelines available

    Data suggest genital screening misses many STI cases in women

    Get CDC fact sheet on shigellosis

    Begin Test

    Buy this Issue/Course

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2020 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing